WEKO3
アイテム
Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail
https://doi.org/10.18999/nagjms.77.1-2.81
https://doi.org/10.18999/nagjms.77.1-2.810d094fc4-44b4-4420-8771-fefe770bc511
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
15_Ishiguro.pdf (425.5 kB)
|
|
| Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2015-02-26 | |||||
| タイトル | ||||||
| タイトル | Efficacy and Safety of Celecoxib Compared with Placebo and Etodolac for Acute Postoperative Pain: A Multicenter, Double-Blind, Randomized, Parallel-Group, Controlled Trail | |||||
| 言語 | en | |||||
| 著者 |
ISHIGURO, NAOKI
× ISHIGURO, NAOKI× HANAOKA, AKIO× OKADA, TOSHIYUKI× ITO, MASANORI |
|||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Celecoxib | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Clinical study | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Placebo | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Etodolac | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Postoperative pain | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Celecoxib is a nonsteroidal anti-inflammatory drug (selective cyclooxygenase-2 inhibitor) that is widely used. The efficacy and safety of celecoxib for treatment of acute postoperative pain were evaluated in Japanese patients. The objective was to assess whether celecoxib showed superiority over placebo treatment and non-inferiority versus etodolac (another selective cyclooxygenase-2 inhibitor) that has been widely used for the management of acute pain. A multicenter, double-blind, randomized, parallel-group, controlled study was performed, in which 616 patients with postoperative pain received celecoxib, etodolac, or placebo. Their impressions of study drug efficacy (overall assessment) and pain intensity were evaluated. Based on each patient’s overall assessment of pain, the efficacy rate was 63.7% in the placebo group, 76.2% in the celecoxib group, and 68.0% in the etodolac group, with these results demonstrating superiority of celecoxib to placebo and noninferiority versus etodolac. The efficacy rate was significantly higher in the celecoxib group than in the etodolac group. There were no adverse events specific to celecoxib, and the safety of celecoxib was similar to that of placebo. Celecoxib was superior to etodolac for controlling acute postoperative pain. | |||||
| 言語 | en | |||||
| 出版者 | ||||||
| 出版者 | Nagoya University School of Medicine | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源 | http://purl.org/coar/resource_type/c_6501 | |||||
| タイプ | departmental bulletin paper | |||||
| 出版タイプ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| ID登録 | ||||||
| ID登録 | 10.18999/nagjms.77.1-2.81 | |||||
| ID登録タイプ | JaLC | |||||
| 関連情報 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | URI | |||||
| 関連識別子 | http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/7712.html | |||||
| ISSN（print） | ||||||
| 収録物識別子タイプ | PISSN | |||||
| 収録物識別子 | 0027-7622 | |||||
| ISSN（Online） | ||||||
| 収録物識別子タイプ | EISSN | |||||
| 収録物識別子 | 2186-3326 | |||||
| 書誌情報 |
en : Nagoya Journal of Medical Science 巻 77, 号 1-2, p. 81-93, 発行日 2015-02 |
|||||
| 著者版フラグ | ||||||
| 値 | publisher | |||||
| URI | ||||||
| 識別子 | http://hdl.handle.net/2237/21261 | |||||
| 識別子タイプ | HDL | |||||
